The field of clinical trials is dynamic, ever-changing, and of paramount importance in advancing healthcare. Clario, a healthcare research technology company, stands at the forefront of this transformative landscape, with a steadfast commitment to improving the way oncology trials are conducted and, ultimately, enhancing the lives of the patients it impacts.
With a 50+ year legacy, Clario has thrived as a trusted and innovative partner for biotech firms, CROs, and pharmaceutical companies. Its dedication to elevating efficacy, ensuring patient safety, and enhancing the quality of life for clinical trial participants has positioned it as a leading pioneer in healthcare research technology, with a primary focus on advancing oncology research and expediting life-saving treatments.
Our dedication to excellence is reflected in our comprehensive understanding of oncology trials, from efficacy and safety to quality of life. Clario’s expertise is essential for the future of oncology research and patient well-being. — Chris Fikry, President & CEO
A standout achievement for Clario is its participation in 75% of all FDA approvals of oncology compounds since 2012, underscoring its remarkable expertise and impact in the field. Its involvement in more than 5,000 oncology trials and enrollment of over one million patients worldwide further exemplify Clario’s unwavering commitment to advancing oncology research and expediting the development of life-saving treatments.
Clario’s comprehensive solutions cover a wide range of endpoint collection technologies, including electronic Clinical Outcome Assessments (eCOA), Cardiac Safety, Medical Imaging, Precision Motion, and Respiratory. its adaptive approach ensures precise data collection across diverse cancer types and study designs.
In the field of oncology clinical trials, Clario’s expertise spans all phases, from Phase I to Phase IV, driven by a dedicated team of scientific experts and operational specialists. Its approach maximizes each trial’s potential, driving valuable insights in oncology research.
With nearly 2,000 imaging oncology studies, Clario excels in response criteria expertise and precise data collection across cancer types, utilizing an adaptable reader platform and cutting-edge technology.
In cardiac safety, Clario’s involvement in over 2,300 trials and contribution to 70+ novel oncology drug approvals highlights its essential role. The company-tailored safety strategies, precision analysis, and global reach ensure a comprehensive understanding of treatment effects and patient safety, upholding its reputation as a trusted name in cardiac safety, dedicated to the success of oncology trials.
Clario places a strong emphasis on patients’ quality of life, employing patient-centric eCOA solutions that enhance data quality and engagement. Its collaboration with Cogstate enables quick and reliable cognitive assessments, giving drug developers a competitive edge in understanding the broader impact of oncology treatments. Clario’s commitment to efficiency is reflected in its rapid deployment of pre-built eCOA oncology assessments, from study design to software release in just five weeks.
Clario’s strategic partnerships with CancerX and the White House Cancer Moonshot underscore its commitment to advancing cancer innovation and improving patient care. Its collaboration with CellCarta streamlines clinical trial sample management for histopathology studies, ensuring end-to-end visibility and digitization of pathology samples.
With a global presence in over 100 countries and a track record contributing to 500+ FDA and EMEA drug approvals involving seven million participants, Clario is well-prepared for reliable and precise trial execution.
In its latest initiative, Clario has partnered with Trial Data to introduce decentralized clinical trial solutions to the Chinese market, combining its expertise in decentralized clinical trials and electronic Clinical Outcome Assessments (eCOA) with Trial Data’s integrated DCT platform, ultimately offering innovative solutions for patient-centric clinical trials in China.
As Clario continues to lead the charge in pioneering innovative solutions for oncology trials, the way forward holds great promise. With its unwavering commitment to patient well-being, safety, and the pursuit of groundbreaking insights, Clario is poised to make further advancements in the field of oncology research.
